|Bid||0.00 x 2200|
|Ask||0.00 x 800|
|Day's Range||79.36 - 85.95|
|52 Week Range||61.58 - 178.71|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||160.29|
Subscribe to Yahoo Finance Plus to view Fair Value for ASND
Biotech stock Ascendis Pharma reversed early losses Thursday to close with a gain despite a first-quarter miss for Skytrofa.
Phase 3 PaTHway Trial top-line results demonstrated potential of TransCon™ PTH to become the first parathyroid replacement therapy for adults with hypoparathyroidismTransCon PTH U.S. FDA regulatory submission on track for Q3 and EU MAA for Q4 2022 Increasing uptake of SKYTROFA® (lonapegsomatropin-tcgd), with more than 1,200 unique patient prescriptions processed as of April 29, 2022Completed U.S. $575 million convertible notes offering strengthening balance sheet to build a sustainable leading g
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.